Combination phentermine and topiramate extended release in the management of obesity

May 12, 2015Expert opinion on pharmacotherapy

Using a combination of phentermine and extended-release topiramate to treat obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Groups prescribed phentermine 15 mg/topiramate ER 92 mg lost an average of 10% of initial weight.

Weight loss from this combination treatment was approximately 8% greater than placebo and 2% greater than a lower dose of the same medications.
Losing weight was linked to a reduced risk of developing type 2 diabetes and improved cardiovascular disease risk factors.
Phentermine-topiramate ER was associated with an increased heart rate, with further investigation needed to determine clinical significance.
Caution is advised when prescribing this medication to women of child-bearing age due to a heightened risk of oral clefts in infants.

AI simplified

INTRODUCTION: Losing ≥ 5% of initial weight improves quality of life and risk factors for cardiovascular disease (CVD) in obese individuals. Lifestyle modification, the cornerstone of weight reduction, may be complemented by pharmacotherapy. In 2012, the FDA approved the combination of phentermine and topiramate extended release (ER) for chronic weight management, as an adjunct to lifestyle modification.

AREAS COVERED: This review examines the safety and efficacy of phentermine-topiramate ER, as determined by randomized controlled trials (RCTs). A preliminary study confirmed the benefit of combining the two medications for improving weight loss and reducing adverse effects, as compared to using equivalent-dose monotherapy alone.

EXPERT OPINION: Across RCTs, groups prescribed phentermine 15 mg/topiramate ER 92 mg lost an average of 10% of initial weight, ∼ 8% more than placebo and 2% more than phentermine 7.5 mg/topiramate 46 mg. Weight loss reduced the risk of developing type 2 diabetes and improved CVD risk factors. Phentermine-topiramate ER, however, was associated with increased heart rate, the clinical significance of which is being investigated in an FDA-required CVD outcomes study. The medication also must be used with caution in women of child-bearing age because of an increased risk to infants of oral cleft.

Full Text

Full text is available at the source.

View full text ↗

Combination phentermine and topiramate extended release in the management of obesity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief